lorazepam and r 121919

lorazepam has been researched along with r 121919 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gutman, DA; Nemeroff, CB; Owens, MJ; Skelton, KH; Thrivikraman, KV	1

Other Studies

1 other study(ies) available for lorazepam and r 121919

Article	Year
The CRF1 receptor antagonist R121919 attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawal. Psychopharmacology, 2007, Volume: 192, Issue:3 Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Flumazenil; Gene Expression; Hypnotics and Sedatives; Hypothalamo-Hypophyseal System; Lorazepam; Male; Neurons; Paraventricular Hypothalamic Nucleus; Pituitary-Adrenal System; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; RNA, Heterogeneous Nuclear; Stress, Physiological; Substance Withdrawal Syndrome; Substance-Related Disorders	2007

Article

Year

The CRF1 receptor antagonist R121919 attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawal.

Psychopharmacology, 2007, Volume: 192, Issue:3

Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Flumazenil; Gene Expression; Hypnotics and Sedatives; Hypothalamo-Hypophyseal System; Lorazepam; Male; Neurons; Paraventricular Hypothalamic Nucleus; Pituitary-Adrenal System; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; RNA, Heterogeneous Nuclear; Stress, Physiological; Substance Withdrawal Syndrome; Substance-Related Disorders

2007